Skip to content

Study · Non-randomized trial · n = 30 · 2014

12 results

Assessing the Effects of Teriparatide Treatment on Bone Mineral Density, Bone Microarchitecture, and Bone Strength.

Kleerekoper M, Greenspan SL, Lewiecki EM, Miller PD, Kendler DL, Maricic M, Keaveny TM, Kopperdahl DL, Ruff VA, Wan X, Janos B, Krohn K

The Journal of bone and joint surgery. American volume4 Jun 2014Cited by 28 (Europe PMC)

PMID24897747 (opens in a new tab)PMCIDPMC6948798 (opens in a new tab)DOI10.2106/jbjs.l.01757 (opens in a new tab)PepBankPUB-24897747
Source linkPubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In women with severe osteoporosis, teriparatide produced no significant change in distal radius microarchitecture assessed by high-resolution MRI.

    In plain wordsIn women with severe osteoporosis, distal radius microarchitecture did not significantly change from baseline during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeDistal radius microarchitecture
    Study

    n: not reported in source

    Comparator
    Baseline
    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/dayAs given in this study (human).

    Source sentences

    Summary
    No significant changes were observed for the primary outcome, high-resolution MRI at the distal aspect of the radius.
    1 context sentence
    Summary · context
    In this phase-4, open-label study, postmenopausal women with severe osteoporosis received 20 μg/day of teriparatide.
  2. 02HumanNon-randomized trialEfficacy outcome

    In women with severe osteoporosis, spine volumetric BMD increased 10.05% from baseline during teriparatide treatment.

    In plain wordsIn women with severe osteoporosis, spine volumetric BMD increased 10.05% from baseline during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseSpine volumetric BMD
    Study

    n = 30

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/day · 18 monthsAs given in this study (human).

    Measurements

    Volumetric BMD change
    10.05%
    spine at month eighteen

    Source sentences

    Summary
    At month eighteen, the least-squares mean percentage change from baseline in total volumetric BMD at the spine was 10.05% (95% confidence interval [CI], 6.83% to 13.26%; p < 0.001), and estimated spine strength increased 17.43% (95% CI, 12.09% to 22.76%; p < 0.001).
    1 context sentence
    Summary · context
    In this phase-4, open-label study, postmenopausal women with severe osteoporosis received 20 μg/day of teriparatide.
  3. 03HumanNon-randomized trialEfficacy outcome

    In women with severe osteoporosis, estimated spine strength increased 17.43% from baseline during teriparatide treatment.

    In plain wordsIn women with severe osteoporosis, estimated spine strength increased 17.43% from baseline during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseEstimated spine strength
    Study

    n = 30

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/day · 18 monthsAs given in this study (human).

    Measurements

    Estimated spine strength change
    17.43%
    spine at month eighteen

    Source sentences

    Summary
    At month eighteen, the least-squares mean percentage change from baseline in total volumetric BMD at the spine was 10.05% (95% confidence interval [CI], 6.83% to 13.26%; p < 0.001), and estimated spine strength increased 17.43% (95% CI, 12.09% to 22.76%; p < 0.001).
    1 context sentence
    Summary · context
    In this phase-4, open-label study, postmenopausal women with severe osteoporosis received 20 μg/day of teriparatide.
  4. 04HumanNon-randomized trialEfficacy outcome

    In women with severe osteoporosis, hip volumetric BMD increased 2.22% from baseline during teriparatide treatment.

    In plain wordsIn women with severe osteoporosis, hip volumetric BMD increased 2.22% from baseline during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseHip volumetric BMD
    Study

    n = 30

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/day · 18 monthsAs given in this study (human).

    Measurements

    Total volumetric BMD change
    2.22%
    hip

    Source sentences

    Summary
    Total volumetric BMD at the hip increased 2.22% (95% CI, 0.37% to 4.06%; p = 0.021), and estimated hip strength increased 2.54% (95% CI, 0.06% to 5.01%; p = 0.045).
    1 context sentence
    Summary · context
    In this phase-4, open-label study, postmenopausal women with severe osteoporosis received 20 μg/day of teriparatide.
  5. 05HumanNon-randomized trialEfficacy outcome

    In women with severe osteoporosis, estimated hip strength increased 2.54% from baseline during teriparatide treatment.

    In plain wordsIn women with severe osteoporosis, estimated hip strength increased 2.54% from baseline during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseEstimated hip strength
    Study

    n = 30

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/day · 18 monthsAs given in this study (human).

    Measurements

    Estimated hip strength change
    2.54%
    hip

    Source sentences

    Summary
    Total volumetric BMD at the hip increased 2.22% (95% CI, 0.37% to 4.06%; p = 0.021), and estimated hip strength increased 2.54% (95% CI, 0.06% to 5.01%; p = 0.045).
    1 context sentence
    Summary · context
    In this phase-4, open-label study, postmenopausal women with severe osteoporosis received 20 μg/day of teriparatide.
  6. 06HumanNon-randomized trialEfficacy outcome

    In women with severe osteoporosis, lumbar spine areal BMD increased during teriparatide treatment.

    In plain wordsIn women with severe osteoporosis, lumbar spine areal BMD increased from baseline during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseLumbar spine areal BMD
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/dayAs given in this study (human).

    Source sentences

    Summary
    Areal BMD increased at the lumbar spine and femoral neck, was unchanged for the total hip and at the distalmost aspect of the radius, and decreased at a point one-third of the distance between the wrist and elbow.
    1 context sentence
    Summary · context
    In this phase-4, open-label study, postmenopausal women with severe osteoporosis received 20 μg/day of teriparatide.
  7. 07HumanNon-randomized trialEfficacy outcome

    In women with severe osteoporosis, femoral neck areal BMD increased during teriparatide treatment.

    In plain wordsIn women with severe osteoporosis, femoral neck areal BMD increased from baseline during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseFemoral neck areal BMD
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/dayAs given in this study (human).

    Source sentences

    Summary
    Areal BMD increased at the lumbar spine and femoral neck, was unchanged for the total hip and at the distalmost aspect of the radius, and decreased at a point one-third of the distance between the wrist and elbow.
    1 context sentence
    Summary · context
    In this phase-4, open-label study, postmenopausal women with severe osteoporosis received 20 μg/day of teriparatide.
  8. 08HumanNon-randomized trialEfficacy outcome

    In women with severe osteoporosis, total hip areal BMD remained unchanged during teriparatide treatment.

    In plain wordsIn women with severe osteoporosis, total hip areal BMD remained unchanged from baseline during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeTotal hip areal BMD
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/dayAs given in this study (human).

    Source sentences

    Summary
    Areal BMD increased at the lumbar spine and femoral neck, was unchanged for the total hip and at the distalmost aspect of the radius, and decreased at a point one-third of the distance between the wrist and elbow.
    1 context sentence
    Summary · context
    In this phase-4, open-label study, postmenopausal women with severe osteoporosis received 20 μg/day of teriparatide.
  9. 09HumanNon-randomized trialEfficacy outcome

    In women with severe osteoporosis, distalmost radius areal BMD remained unchanged during teriparatide treatment.

    In plain wordsIn women with severe osteoporosis, distalmost radius areal BMD remained unchanged from baseline during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeDistalmost radius areal BMD
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/dayAs given in this study (human).

    Source sentences

    Summary
    Areal BMD increased at the lumbar spine and femoral neck, was unchanged for the total hip and at the distalmost aspect of the radius, and decreased at a point one-third of the distance between the wrist and elbow.
    1 context sentence
    Summary · context
    In this phase-4, open-label study, postmenopausal women with severe osteoporosis received 20 μg/day of teriparatide.
  10. 10HumanNon-randomized trialEfficacy outcome

    In women with severe osteoporosis, areal BMD decreased at the one-third radius site during teriparatide treatment.

    In plain wordsIn women with severe osteoporosis, areal BMD decreased from baseline at the one-third radius site during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseOne-third radius areal BMD
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/dayAs given in this study (human).

    Source sentences

    Summary
    Areal BMD increased at the lumbar spine and femoral neck, was unchanged for the total hip and at the distalmost aspect of the radius, and decreased at a point one-third of the distance between the wrist and elbow.
    1 context sentence
    Summary · context
    In this phase-4, open-label study, postmenopausal women with severe osteoporosis received 20 μg/day of teriparatide.
  11. 11HumanNon-randomized trialEfficacy outcome

    In women with severe osteoporosis, bone turnover markers increased at months three, six, and twenty-four during teriparatide treatment.

    In plain wordsIn women with severe osteoporosis, bone turnover markers increased from baseline at months three, six, and twenty-four during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBone turnover markers
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/dayAs given in this study (human).

    Source sentences

    Summary
    Bone turnover markers increased at months three, six, and twenty-four (all p < 0.05).
    1 context sentence
    Summary · context
    In this phase-4, open-label study, postmenopausal women with severe osteoporosis received 20 μg/day of teriparatide.
  12. 12HumanNon-randomized trialSafety outcome

    In women with severe osteoporosis receiving teriparatide, no unexpected adverse events were observed.

    In plain wordsIn women with severe osteoporosis receiving teriparatide, no unexpected adverse events were observed.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableUnexpected adverse events
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    20 μg/dayAs given in this study (human).

    Source sentences

    Summary
    No unexpected adverse events were observed.
    1 context sentence
    Summary · context
    In this phase-4, open-label study, postmenopausal women with severe osteoporosis received 20 μg/day of teriparatide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.